Inception IBD Inc.

Celgene Corp. 's aggressive deal-making strategy could pay off in a big way over the next several years, bringing in billions of dollars in annual sales from new drugs to diversify revenue beyond its

IN VITRO DIAGNOSTICS Alliances AEterna Zentaris Inc. Armune BioScience Inc. Armune BioScience Inc. granted AEterna Zentaris Inc. rights to sell its Apifiny prostate cancer diagnostic to desi

Necessity mothered the build-to-buy strategy. Some thought good times might kill it. At a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate

IN VITRO DIAGNOSTICS AltheaDx Inc. AltheaDx 's Series C brings in $30mm AltheaDx Inc. (oncology R&D services and personalized medicine focused on cardio, neuro, and blood disorders) brought in